1-benzylpiperazine

1-benzylpiperazine (BZP) is a synthetic psychoactive small molecule and central nervous system (CNS) stimulant. Originally synthesized in 1944 by Burroughs Wellcome & Co. as a potential anthelmintic agent and later investigated in the 1970s as an antidepressant, BZP was abandoned due to its amphetamine-like stimulant properties and high potential for abuse. It acts as a monoamine releaser and reuptake inhibitor, primarily targeting the sodium-dependent dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT), while also acting as an agonist at various serotonin receptors (such as 5-HT2A, 5-HT2B, and 5-HT3) and an antagonist at alpha-2 adrenergic receptors. In the early 2000s, BZP gained widespread popularity as a legal alternative to amphetamine and MDMA, sold in recreational 'party pills' (often combined with TFMPP). Following safety concerns, including reports of seizures, psychosis, and cardiovascular toxicity, BZP has been classified as a controlled substance in many jurisdictions, including New Zealand, the European Union, and the United States.

Brand names

A2A-2A 2BlissChargeFrenzyHerbal EcstasyRapture

Other names

1-benzylpiperazinebenzylpiperazineBZPN-benzylpiperazine